J.L. Misset

947 total citations
39 papers, 733 citations indexed

About

J.L. Misset is a scholar working on Oncology, Hematology and Genetics. According to data from OpenAlex, J.L. Misset has authored 39 papers receiving a total of 733 indexed citations (citations by other indexed papers that have themselves been cited), including 20 papers in Oncology, 11 papers in Hematology and 9 papers in Genetics. Recurrent topics in J.L. Misset's work include Cancer Treatment and Pharmacology (10 papers), Chronic Lymphocytic Leukemia Research (6 papers) and Acute Myeloid Leukemia Research (5 papers). J.L. Misset is often cited by papers focused on Cancer Treatment and Pharmacology (10 papers), Chronic Lymphocytic Leukemia Research (6 papers) and Acute Myeloid Leukemia Research (5 papers). J.L. Misset collaborates with scholars based in France, United States and Netherlands. J.L. Misset's co-authors include I Blazsek, François Goldwasser, J. Alexandre, J.M. Gornet, Bruno Falissard, Martine Comisso, Yvan Touitou, A Bogdan, Manuel Benavides and Esteban Cvitkovic and has published in prestigious journals such as Journal of Clinical Oncology, Cancer and British Journal of Cancer.

In The Last Decade

J.L. Misset

38 papers receiving 701 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
J.L. Misset France 13 357 143 124 121 120 39 733
H. Tzvi Thaler United States 10 189 0.5× 125 0.9× 136 1.1× 100 0.8× 150 1.3× 13 738
Miroslaw Mazurczak United States 12 391 1.1× 93 0.7× 109 0.9× 243 2.0× 78 0.7× 22 772
Richard J. Kaufman United States 16 553 1.5× 187 1.3× 205 1.7× 113 0.9× 113 0.9× 34 1.1k
Konstantinos Papadimitriou Greece 12 340 1.0× 120 0.8× 92 0.7× 150 1.2× 67 0.6× 51 724
Mi‐Jung Kim South Korea 13 366 1.0× 106 0.7× 108 0.9× 232 1.9× 116 1.0× 39 720
Silvia Carpano Italy 14 388 1.1× 58 0.4× 210 1.7× 103 0.9× 130 1.1× 42 708
B Neri Italy 15 233 0.7× 59 0.4× 200 1.6× 104 0.9× 29 0.2× 46 627
Julia Alcaide Spain 14 285 0.8× 65 0.5× 112 0.9× 91 0.8× 95 0.8× 60 605
Shipra Gandhi United States 16 442 1.2× 220 1.5× 177 1.4× 204 1.7× 56 0.5× 89 868

Countries citing papers authored by J.L. Misset

Since Specialization
Citations

This map shows the geographic impact of J.L. Misset's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by J.L. Misset with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites J.L. Misset more than expected).

Fields of papers citing papers by J.L. Misset

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by J.L. Misset. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by J.L. Misset. The network helps show where J.L. Misset may publish in the future.

Co-authorship network of co-authors of J.L. Misset

This figure shows the co-authorship network connecting the top 25 collaborators of J.L. Misset. A scholar is included among the top collaborators of J.L. Misset based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with J.L. Misset. J.L. Misset is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Misset, J.L., et al.. (2012). Mélanome et grossesse. Annales de Dermatologie et de Vénéréologie. 139(4). 298–304. 4 indexed citations
2.
Marec‐Bérard, Perrine, Pascal Chastagner, Diana Kassab‐Chahmi, et al.. (2009). 2007 Standards, Options, and Recommendations: Use of erythropoiesis‐stimulating agents (ESA: epoetin alfa, epoetin beta, and darbepoetin) for the management of anemia in children with cancer. Pediatric Blood & Cancer. 53(1). 7–12. 8 indexed citations
3.
Michalski, Michelle L., Dominique Gossot, Francesco Savinelli, et al.. (2007). Douleur abdominale au cours de l’évolution d’un cancer bronchique. Revue de Pneumologie Clinique. 63(2). 100–103. 2 indexed citations
4.
5.
Goldwasser, François, Nadine Houédé, F. Bertheault-Cvitkovic, et al.. (2006). Irofulven (IROF) combined with oxaliplatin (OXA) in advanced hepatocellular carcinoma (HCC) patients (pts): Phase I study (preliminary results). Journal of Clinical Oncology. 24(18_suppl). 14082–14082. 1 indexed citations
6.
Coudert, Bruno, Laurent Arnould, L. Moreau, et al.. (2005). Pre-operative systemic (neo-adjuvant) therapy with trastuzumab and docetaxel for HER2-overexpressing stage II or III breast cancer: results of a multicenter phase II trial. Annals of Oncology. 17(3). 409–414. 77 indexed citations
7.
Hennequin, Christophe, Marc Espié, J.L. Misset, & C Maylin. (2004). La chimiothérapie première permet-elle réellement d’augmenter le taux de conservation mammaire ?. Cancer/Radiothérapie. 8(1). 48–53. 6 indexed citations
8.
9.
Kesteren, Charlotte van, Esteban Cvitkovic, A. Taamma, et al.. (2001). A comparison of limited sampling strategies for prediction of Ecteinascidin 743 clearance when administered as a 24-h infusion. Cancer Chemotherapy and Pharmacology. 48(6). 459–466. 11 indexed citations
10.
Kesteren, Charlotte van, Esteban Cvitkovic, A. Taamma, et al.. (2000). Pharmacokinetics and pharmacodynamics of the novel marine-derived anticancer agent ecteinascidin 743 in a phase I dose-finding study.. PubMed. 6(12). 4725–32. 72 indexed citations
11.
Brain, Étienne, et al.. (1999). Primary chemotherapy or hormonotherapy for patients with breast cancer. Cancer Treatment Reviews. 25(4). 187–197.
12.
Misset, J.L.. (1998). Oxaliplatin in practice. British Journal of Cancer. 77(S4). 4–7. 91 indexed citations
13.
Bozec, Laurence, Philippe Bierling, Patricia Fromont, et al.. (1998). Irinotecan-induced immune thrombocytopenia. Annals of Oncology. 9(4). 453–455. 14 indexed citations
14.
Faivre, Sandrine, et al.. (1997). Paclitaxel (Taxol?? )-associated junctional tachycardia. Anti-Cancer Drugs. 8(7). 714–716. 2 indexed citations
15.
Massari, Claire, et al.. (1995). HPLC determination of the stability of retinoic acid in ovule formulations for the treatment of cervical dysplasia related to papillomavirus. International Journal of Pharmaceutics. 115(2). 235–240. 3 indexed citations
16.
Touitou, Yvan, et al.. (1995). Rhythm alteration in patients with metastatic breast cancer and poor prognostic factors. Journal of Cancer Research and Clinical Oncology. 121(3). 181–188. 77 indexed citations
17.
Frénoy, N, et al.. (1994). Application of a new protocol for nested PCR to the detection of minimal residual bcr/abl transcripts.. PubMed. 8(8). 1411–4. 8 indexed citations
18.
Blazsek, I, Martine Comisso, & J.L. Misset. (1991). Modulation of bone marrow cell functions in vitro by Bestatin (ubenimex). Biomedicine & Pharmacotherapy. 45(2-3). 81–86. 4 indexed citations
19.
Stroup, Robert, et al.. (1990). Surface immunoglobulin-positive lymphoblastic lymphoma a report of three cases. Cancer. 65(11). 2559–2563. 4 indexed citations
20.
Machover, D., Henry Rappaport, L Schwarzenberg, et al.. (1984). Treatment of acute myeloid leukemia with a combination of intensive induction chemotherapy, early consolidation, splenectomy and long‐term maintenance chemotherapy. Cancer. 53(8). 1644–1650. 10 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by H. Tzvi Thaler Breakdown of academic impact, for papers by Miroslaw Mazurczak Breakdown of academic impact, for papers by Richard J. Kaufman Breakdown of academic impact, for papers by Konstantinos Papadimitriou Breakdown of academic impact, for papers by Mi‐Jung Kim Breakdown of academic impact, for papers by Silvia Carpano Breakdown of academic impact, for papers by B Neri Breakdown of academic impact, for papers by Julia Alcaide Breakdown of academic impact, for papers by Shipra Gandhi
Rankless by CCL
2026